Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas

Xuhan Zhang, Lu Liu, Shiyong Zhou, Kuo Zhao, Zheng Song, Ge Hu, Tingting Zhang, Yang Li, Lihua Qiu, Lanfang Li, Zhengzi Qian, Bin Meng, Yi Pan, Xiubao Ren, Xianhuo Wang, Huilai Zhang, Kai Fu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Immune checkpoints, including PD-1/PD-L1, play an important role in immunosuppression in various malignancies. Elevated levels of soluble programmed death ligand 1 (sPD-L1) are associated with worse prognosis in multiple myeloma and diffuse large B cell lymphoma. Herein, the purpose of this study is to investigate the relationships between plasma sPD-L1 levels and clinical response in peripheral T-cell lymphoma (PTCL) patients. A total of 37 PTCL patients and 20 healthy volunteers were enrolled. Peripheral blood from patients was collected prior to systemic therapy. Plasma levels of sPD-L1 and IFN-γ were measured by enzyme-linked immunosorbent assay (ELISA). PD-L1 expression in tissues was detected by immunohistochemistry (IHC). Clinical response for patients was evaluated. ONCOMINE database analyses showed that PD-L1 mRNA expression was significantly upregulated in PTCLs. The median sPD-L1 level was 0.729 ng/mL for 20 healthy volunteers and 1.696 ng/mL for 37 PTCL patients which was significantly higher than that in healthy volunteers (0.000). The sPD-L1 level was positively correlated with IFN-γ level (0.000, r = 0.849) and was also positively associated with clinical staging (0.045), LDH level (0.003), and β2-MG level (0.045). Patients with high sPD-L1 level had lower overall response rate than those with low sPD-L1 level (88.9% vs 50.0%, 0.022) and tended to have poorer PFS and OS. PD-L1 expression in tissues matched very well with the sPD-L1 level in PTCL patients. In conclusion, PTCL patients had higher sPD-L1 level compared with healthy volunteers. High sPD-L1 level was correlated with worse clinical response, suggesting that sPD-L1 level was an underlying plasma biomarker to predict the prognosis for PTCL patients.

Original languageEnglish (US)
Pages (from-to)270-276
Number of pages7
JournalHematological Oncology
Volume37
Issue number3
DOIs
StatePublished - Jan 1 2019

Fingerprint

Peripheral T-Cell Lymphoma
Ligands
Healthy Volunteers
Lymphoma, Large B-Cell, Diffuse
Multiple Myeloma
Immunosuppression
Biomarkers

Keywords

  • IFN-γ
  • PTCLs
  • clinical response
  • sPD-L1

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas. / Zhang, Xuhan; Liu, Lu; Zhou, Shiyong; Zhao, Kuo; Song, Zheng; Hu, Ge; Zhang, Tingting; Li, Yang; Qiu, Lihua; Li, Lanfang; Qian, Zhengzi; Meng, Bin; Pan, Yi; Ren, Xiubao; Wang, Xianhuo; Zhang, Huilai; Fu, Kai.

In: Hematological Oncology, Vol. 37, No. 3, 01.01.2019, p. 270-276.

Research output: Contribution to journalArticle

Zhang, X, Liu, L, Zhou, S, Zhao, K, Song, Z, Hu, G, Zhang, T, Li, Y, Qiu, L, Li, L, Qian, Z, Meng, B, Pan, Y, Ren, X, Wang, X, Zhang, H & Fu, K 2019, 'Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas', Hematological Oncology, vol. 37, no. 3, pp. 270-276. https://doi.org/10.1002/hon.2636
Zhang, Xuhan ; Liu, Lu ; Zhou, Shiyong ; Zhao, Kuo ; Song, Zheng ; Hu, Ge ; Zhang, Tingting ; Li, Yang ; Qiu, Lihua ; Li, Lanfang ; Qian, Zhengzi ; Meng, Bin ; Pan, Yi ; Ren, Xiubao ; Wang, Xianhuo ; Zhang, Huilai ; Fu, Kai. / Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas. In: Hematological Oncology. 2019 ; Vol. 37, No. 3. pp. 270-276.
@article{784ddff9120545bfb4258518b1e04dba,
title = "Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas",
abstract = "Immune checkpoints, including PD-1/PD-L1, play an important role in immunosuppression in various malignancies. Elevated levels of soluble programmed death ligand 1 (sPD-L1) are associated with worse prognosis in multiple myeloma and diffuse large B cell lymphoma. Herein, the purpose of this study is to investigate the relationships between plasma sPD-L1 levels and clinical response in peripheral T-cell lymphoma (PTCL) patients. A total of 37 PTCL patients and 20 healthy volunteers were enrolled. Peripheral blood from patients was collected prior to systemic therapy. Plasma levels of sPD-L1 and IFN-γ were measured by enzyme-linked immunosorbent assay (ELISA). PD-L1 expression in tissues was detected by immunohistochemistry (IHC). Clinical response for patients was evaluated. ONCOMINE database analyses showed that PD-L1 mRNA expression was significantly upregulated in PTCLs. The median sPD-L1 level was 0.729 ng/mL for 20 healthy volunteers and 1.696 ng/mL for 37 PTCL patients which was significantly higher than that in healthy volunteers (0.000). The sPD-L1 level was positively correlated with IFN-γ level (0.000, r = 0.849) and was also positively associated with clinical staging (0.045), LDH level (0.003), and β2-MG level (0.045). Patients with high sPD-L1 level had lower overall response rate than those with low sPD-L1 level (88.9{\%} vs 50.0{\%}, 0.022) and tended to have poorer PFS and OS. PD-L1 expression in tissues matched very well with the sPD-L1 level in PTCL patients. In conclusion, PTCL patients had higher sPD-L1 level compared with healthy volunteers. High sPD-L1 level was correlated with worse clinical response, suggesting that sPD-L1 level was an underlying plasma biomarker to predict the prognosis for PTCL patients.",
keywords = "IFN-γ, PTCLs, clinical response, sPD-L1",
author = "Xuhan Zhang and Lu Liu and Shiyong Zhou and Kuo Zhao and Zheng Song and Ge Hu and Tingting Zhang and Yang Li and Lihua Qiu and Lanfang Li and Zhengzi Qian and Bin Meng and Yi Pan and Xiubao Ren and Xianhuo Wang and Huilai Zhang and Kai Fu",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/hon.2636",
language = "English (US)",
volume = "37",
pages = "270--276",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas

AU - Zhang, Xuhan

AU - Liu, Lu

AU - Zhou, Shiyong

AU - Zhao, Kuo

AU - Song, Zheng

AU - Hu, Ge

AU - Zhang, Tingting

AU - Li, Yang

AU - Qiu, Lihua

AU - Li, Lanfang

AU - Qian, Zhengzi

AU - Meng, Bin

AU - Pan, Yi

AU - Ren, Xiubao

AU - Wang, Xianhuo

AU - Zhang, Huilai

AU - Fu, Kai

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Immune checkpoints, including PD-1/PD-L1, play an important role in immunosuppression in various malignancies. Elevated levels of soluble programmed death ligand 1 (sPD-L1) are associated with worse prognosis in multiple myeloma and diffuse large B cell lymphoma. Herein, the purpose of this study is to investigate the relationships between plasma sPD-L1 levels and clinical response in peripheral T-cell lymphoma (PTCL) patients. A total of 37 PTCL patients and 20 healthy volunteers were enrolled. Peripheral blood from patients was collected prior to systemic therapy. Plasma levels of sPD-L1 and IFN-γ were measured by enzyme-linked immunosorbent assay (ELISA). PD-L1 expression in tissues was detected by immunohistochemistry (IHC). Clinical response for patients was evaluated. ONCOMINE database analyses showed that PD-L1 mRNA expression was significantly upregulated in PTCLs. The median sPD-L1 level was 0.729 ng/mL for 20 healthy volunteers and 1.696 ng/mL for 37 PTCL patients which was significantly higher than that in healthy volunteers (0.000). The sPD-L1 level was positively correlated with IFN-γ level (0.000, r = 0.849) and was also positively associated with clinical staging (0.045), LDH level (0.003), and β2-MG level (0.045). Patients with high sPD-L1 level had lower overall response rate than those with low sPD-L1 level (88.9% vs 50.0%, 0.022) and tended to have poorer PFS and OS. PD-L1 expression in tissues matched very well with the sPD-L1 level in PTCL patients. In conclusion, PTCL patients had higher sPD-L1 level compared with healthy volunteers. High sPD-L1 level was correlated with worse clinical response, suggesting that sPD-L1 level was an underlying plasma biomarker to predict the prognosis for PTCL patients.

AB - Immune checkpoints, including PD-1/PD-L1, play an important role in immunosuppression in various malignancies. Elevated levels of soluble programmed death ligand 1 (sPD-L1) are associated with worse prognosis in multiple myeloma and diffuse large B cell lymphoma. Herein, the purpose of this study is to investigate the relationships between plasma sPD-L1 levels and clinical response in peripheral T-cell lymphoma (PTCL) patients. A total of 37 PTCL patients and 20 healthy volunteers were enrolled. Peripheral blood from patients was collected prior to systemic therapy. Plasma levels of sPD-L1 and IFN-γ were measured by enzyme-linked immunosorbent assay (ELISA). PD-L1 expression in tissues was detected by immunohistochemistry (IHC). Clinical response for patients was evaluated. ONCOMINE database analyses showed that PD-L1 mRNA expression was significantly upregulated in PTCLs. The median sPD-L1 level was 0.729 ng/mL for 20 healthy volunteers and 1.696 ng/mL for 37 PTCL patients which was significantly higher than that in healthy volunteers (0.000). The sPD-L1 level was positively correlated with IFN-γ level (0.000, r = 0.849) and was also positively associated with clinical staging (0.045), LDH level (0.003), and β2-MG level (0.045). Patients with high sPD-L1 level had lower overall response rate than those with low sPD-L1 level (88.9% vs 50.0%, 0.022) and tended to have poorer PFS and OS. PD-L1 expression in tissues matched very well with the sPD-L1 level in PTCL patients. In conclusion, PTCL patients had higher sPD-L1 level compared with healthy volunteers. High sPD-L1 level was correlated with worse clinical response, suggesting that sPD-L1 level was an underlying plasma biomarker to predict the prognosis for PTCL patients.

KW - IFN-γ

KW - PTCLs

KW - clinical response

KW - sPD-L1

UR - http://www.scopus.com/inward/record.url?scp=85066474383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066474383&partnerID=8YFLogxK

U2 - 10.1002/hon.2636

DO - 10.1002/hon.2636

M3 - Article

C2 - 31074879

AN - SCOPUS:85066474383

VL - 37

SP - 270

EP - 276

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 3

ER -